Skip to main content

fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®)

 

Following a full submission

AWMSG advice
Status: Recommended

Fluticasone furoate / vilanterol (Relvar® Ellipta®) is recommended as an option for use within NHS Wales for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.
 Final Recommendation: fluticasonea vilanterol (Relvar Ellipta) 1216 (PDF, 283Kb)
 Appraisal Report: fluticasone vilanterol (RelvarEllipta) 1216 (PDF, 2.0Mb)

Medicine details
Medicine name fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®)
Formulation 92 micrograms/22 micrograms inhalation powder
Reference number 1216
Indication

Regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists
Company GlaxoSmithKline
BNF chapter Respiratory system
Assessment type Full
Status Recommended
Advice number 2014
NMG meeting date 18/06/2014
AWMSG meeting date 16/07/2014
Ratification by Welsh Government 13/08/2014
Date of issue 14/08/2014
Date of last review 13/12/2017
Follow AWTTC: